Advertisement
Table 1 Selected patient and tumor characteristics
| Characteristics | Total (N = 819) |
|---|---|
| N (%) | |
| Age (in years) | |
| <50 | 348 (42.5) |
| ≥50 | 471 (57.5) |
| NPI score | |
| Median (range) | 5.52 (3.0–9.0) |
| Treatment group | |
| E-CMF | 123 (15.0) |
| E-T-CMF | 392 (47.9) |
| ET-CMF | 304 (37.1) |
| Menopausal status | |
| Premenopausal | 375 (45.8) |
| Postmenopausal | 444 (54.2) |
| Breast surgery | |
| Modified radical mastectomy | 579 (70.7) |
| Breast-conserving surgery | 240 (29.3) |
| ER/PgR status | |
| Negative | 165 (21.7) |
| Positive | 596 (78.3) |
| Histological grade | |
| I–II | 406 (49.6) |
| III–Undifferentiated | 413 (50.4) |
| Tumor size (cm) | |
| ≤2 | 181 (22.8) |
| 2–5 | 517 (65.2) |
| >5 | 95 (12.0) |
| Positive lymph nodes | |
| 1–3 nodes | 331 (40.5) |
| ≥4 nodes | 487 (59.5) |
| Adjuvant radiation therapy | |
| No | 184 (23.2) |
| Yes | 609 (76.8) |
| Adjuvant hormonal therapy | |
| No | 154 (18.9) |
| Yes | 661 (81.1) |
| Bone metastases | |
| No | 711 (88.4) |
| Yes | 93 (11.6) |
| HER2 status | |
| Negative | 593 (76.5) |
| Positive | 182 (23.5) |
| Ki67 protein expression | |
| Low (<20%) | 367 (44.8) |
| High (≥20%) | 452 (55.2) |
| Subtypes | |
| Luminal A | 245 (32.3) |
| Luminal B | 248 (32.8) |
| Luminal-HER2 | 99 (13.1) |
| HER2-enriched | 79 (10.4) |
| Triple-negative | 86 (11.4) |
| OPN mRNA expression | |
| Low (<50th percentile) | 407 (50.0) |
| High (≥50th percentile) | 407 (50.0) |
| OPN protein expression | |
| Low (0–4 Allred score) | 59 (10.8) |
| High (5–8 Allred score) | 487 (89.2) |
